|
1
|
Hsiang YH, Hertzberg R, Hecht S and Liu
LF: Camptothecin induces protein-linked DNA breaks via mammalian
DNA topoisomerase I. J Biol Chem. 260:14873–14878. 1985.PubMed/NCBI
|
|
2
|
Masuda N, Kudoh S and Fukuoka M:
Irinotecan (CPT-11): pharmacology and clinical applications. Crit
Rev Oncol Hematol. 24:3–26. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hecht JR: Gastrointestinal toxicity or
irinotecan. Oncology (Williston Park). 12:72–78. 1998.PubMed/NCBI
|
|
4
|
Pizzolato JF and Saltz LB: The
camptothecins. Lancet. 361:2235–2242. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Abigerges D, Armand JP, Chabot GG, et al:
Irinotecan (CPT-11) high-dose escalation using intensive high-dose
loperamide to control diarrhea. J Natl Cancer Inst. 86:446–449.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mori K, Kondo T, Kamiyama Y, Kano Y and
Tominaga K: Preventive effect of Kampo medicine (Hangeshashin-to)
against irinotecan-induced diarrhea in advanced non-small-cell lung
cancer. Cancer Chemother Pharmacol. 51:403–406. 2003.PubMed/NCBI
|
|
7
|
Kehrer DF, Sparreboom A, Verweij J, et al:
Modulation of irinotecan-induced diarrhea by cotreatment with
neomycin in cancer patients. Clin Cancer Res. 7:1136–1141.
2001.PubMed/NCBI
|
|
8
|
Alimonti A, Satta F, Pavese I, Burattini
E, Zoffoli V and Vecchione A: Prevention of irinotecan plus
5-fluorouracil/leucovorin-induced diarrhoea by oral administration
of neomycin plus bacitracin in first-line treatment of advanced
colorectal cancer. Ann Oncol. 14:805–806. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Furman WL, Crews KR, Billups C, et al:
Cefixime allows greater dose escalation of oral irinotecan: a phase
I study in pediatric patients with refractory solid tumors. J Clin
Oncol. 24:563–570. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takeda Y, Kobayashi K, Akiyama Y, et al:
Prevention of irinotecan (CPT-11)-induced diarrhea by oral
alkalization combined with control of defecation in cancer
patients. Int J Cancer. 92:269–275. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Michael M, Brittain M, Nagai J, et al:
Phase II study of activated charcoal to prevent irinotecan-induced
diarrhea. J Clin Oncol. 22:4410–4417. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hidaka M, Yamasaki K, Okumura M, et al:
Adsorption of irinotecan onto oral adsorbent AST-120 (Kremezin) for
preventing delayed diarrhea. Cancer Chemother Pharmacol.
59:321–328. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ychou M, Douillard JY, Rougier P, et al:
Randomized comparison of prophylactic antidiarrheal treatment
versus no prophylactic antidiarrheal treatment in patients
receiving CPT-11 (irinotecan) for advanced 5-FU-resistant
colorectal cancer: an open-label multicenter phase II study. Am J
Clin Oncol. 23:143–148. 2000. View Article : Google Scholar
|
|
14
|
Savarese DM, Halabi S, Hars V, et al:
Phase II study of docetaxel, estramustine, and low-dose
hydrocortisone in men with hormone-refractory prostate cancer: a
final report of CALGB 9780. Cancer and Leukemia Group B. J Clin
Oncol. 19:2509–2516. 2001.PubMed/NCBI
|
|
15
|
Lenfers BH, Loeffler TM, Droege CM and
Hausamen TU: Substantial activity of budesonide in patients with
irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure
of loperamide treatment. Ann Oncol. 10:1251–1253. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iyer L, King CD, Whitington PF, et al:
Genetic predisposition to the metabolism of irinotecan (CPT-11).
Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in
the glucuronidation of its active metabolite (SN-38) in human liver
microsomes. J Clin Invest. 101:847–854. 1998. View Article : Google Scholar
|
|
17
|
Rivory LP and Robert J: Identification and
kinetics of a beta-glucuronide metabolite of SN-38 in human plasma
after administration of the camptothecin derivative irinotecan.
Cancer Chemother Pharmacol. 36:176–179. 1995. View Article : Google Scholar
|
|
18
|
Itoh T, Takemoto I, Itagaki S, Sasaki K,
Hirano T and Iseki K: Biliary excretion of irinotecan and its
metabolites. J Pharm Pharm Sci. 7:13–18. 2004.PubMed/NCBI
|
|
19
|
Araki E, Ishikawa M, Iigo M, Koide T,
Itabashi M and Hoshi A: Relationship between development of
diarrhea and the concentration of SN-38, an active metabolite of
CPT-11, in the intestine and the blood plasma of athymic mice
following intraperitoneal administration of CPT-11. Jpn J Cancer
Res. 84:697–702. 1993. View Article : Google Scholar
|
|
20
|
Ikegami T, Ha L, Arimori K, et al:
Intestinal alkalization as a possible preventive mechanism in
irinotecan (CPT-11)-induced diarrhea. Cancer Res. 62:179–187.
2002.PubMed/NCBI
|
|
21
|
Ikuno N, Soda H, Watanabe M and Oka M:
Irinotecan (CPT-11) and characteristic mucosal changes in the mouse
ileum and cecum. J Natl Cancer Inst. 87:1876–1883. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Takasuna K, Hagiwara T, Hirohashi M, et
al: Involvement of beta-glucuronidase in intestinal microflora in
the intestinal toxicity of the antitumor camptothecin derivative
irinotecan hydrochloride (CPT-11) in rats. Cancer Res.
56:3752–3757. 1996.
|
|
23
|
Alimonti A, Gelibter A, Pavese I, et al:
New approaches to prevent intestinal toxicity of irinotecan-based
regimens. Cancer Treat Rev. 30:555–562. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Saliba F, Hagipantelli R, Misset JL, et
al: Pathophysiology and therapy of irinotecan-induced delayed-onset
diarrhea in patients with advanced colorectal cancer: a prospective
assessment. J Clin Oncol. 16:2745–2751. 1998.PubMed/NCBI
|
|
25
|
Holdeman LV, Cato EP and Moore WEC:
Anaerobe Laboratory Manual. 4th edition. Virginia Polytechnic
Institute and State University; Blacksburg: 1977
|
|
26
|
Kurita A and Kaneda N: High-performance
liquid chromatographic method for the simultaneous determination of
the camptothecin derivative irinotecan hydrochloride, CPT-11, and
its metabolites SN-38 and SN-38 glucuronide in rat plasma with a
fully automated on-line solid-phase extraction system, PROSPEKT. J
Chromatogr B Biomed Sci Appl. 724:335–344. 1999.
|
|
27
|
Kaneda N, Kurita A, Hosokawa Y, Yokokura T
and Awazu S: Intravenous administration of irinotecan elevates the
blood beta-glucuronidase activity in rats. Cancer Res.
57:5305–5308. 1997.PubMed/NCBI
|
|
28
|
Yamamoto M, Kurita A, Asahara T, et al:
Metabolism of irinotecan and its active metabolite SN-38 by
intestinal microflora in rats. Oncol Rep. 20:727–730.
2008.PubMed/NCBI
|
|
29
|
Beretta GL and Zunino F: Relevance of
extracellular and intracellular interactions of camptothecins as
determinants of antitumor activity. Biochem Pharmacol.
74:1437–1444. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Burke TG and Mi Z: The structural basis of
camptothecin interactions with human serum albumin: impact on drug
stability. J Med Chem. 37:40–46. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takasuna K, Hagiwara T, Watanabe K, et al:
Optimal antidiarrhea treatment for antitumor agent irinotecan
hydrochloride (CPT-11)-induced delayed diarrhea. Cancer Chemother
Pharmacol. 58:494–503. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fittkau M, Voigt W, Holzhausen HJ and
Schmoll HJ: Saccharic acid 1.4-lactone protects against
CPT-11-induced mucosa damage in rats. J Cancer Res Clin Oncol.
130:388–394. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kurita A, Kado S, Matsumoto T, et al:
Streptomycin alleviates irinotecan-induced delayed-onset diarrhea
in rats by a mechanism other than inhibition of beta-glucuronidase
activity in intestinal lumen. Cancer Chemother Pharmacol.
67:201–213. 2011. View Article : Google Scholar
|
